Table 4.

Effect of Buprenorphine on Darunavir and Amprenavir Concentrations^a

Pharmacokinetic Parameter	Buprenorphine-Naloxone Group	Control Group	P Value
Darunavir (n = 11 in each group)
AUC0–24, h*μg/mL	79.4 (18.0)	71.0 (19.7)	.31
CL/F, L/h	10.54 (2.32)	11.94 (2.74)	.21
Cmax, μg/mL	7.2 (1.2)	6.9 (1.4)	.54
Tmax, hours, median (range)	4.0 (1.0–6.0)	2.0 (1.5–6.0)	.85
T1/2, hours	18.7 (8.1)	15.9 (9.8)	.28
Amprenavir (active metabolite of fosamprenavir; n = 10 in each group)
AUC0–24, h*μg/mL	67.4 (24.3)	71.2 (36.3)	.79
CL/F, L/h	24.5 (12.6)	29.2 (24.0)	.59
Cmax, μg/mL	7.2 (2.7)	7.5 (4.7)	.86
Tmax, hours, median (range)	2.5 (1.0–4.0)	3.5 (1.0–4.0)	.34
T1/2, hours	23.1 (15.0)	17.3 (9.7)	.32

Abbreviations: AUC, area under the concentration time curve; C₂₄, trough plasma concentration; C_max, maximum plasma concentration; CL/F, bioavailability-adjusted clearance; T_max, time of C_max; T_1/2, elimination half-life.

^aData are mean (standard error) values, unless otherwise indicated. All parameter values are adjusted to a standard dose of 16 mg of buprenorphine daily.